13D Filing: Ventech Capital II and Eyegate Pharmaceuticals Inc (EYEG)

Page 2 of 11

Page 2 of 11 – SEC Filing

CUSIP No. 30233M 107 13D Page 2 of 11
1

NAMES OF REPORTING PERSONS.

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).

FCPR Ventech A

2

Check The Appropriate
Box If A Member Of A Group

(a) o

(b) o

3

SEC USE ONLY

 

4

SOURCE OF FUNDS

WC

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) o
6

CITIZENSHIP OR PLACE OF ORGANIZATION

France

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
7

SOLE VOTING POWER

574,763 shares*

8

SHARED VOTING POWER

0 shares

9 SOLE DISPOSITIVE POWER
574,763 shares*
10

SHARED DISPOSITIVE POWER

0 shares

11

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON

574,763 shares*

12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  o
13

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

3.5%**

14

TYPE OF REPORTING PERSON

OO

*Includes 62,384 shares of Common Stock issuable upon exercise
of warrants beneficially owned by the Reporting Person.

** The percentage was calculated based on the 16,274,778 shares
of Common Stock outstanding as of June 14, 2017 as reported in the Issuer’s Prospectus pursuant to Rule 424(b)(4) filed
with the Securities and Exchange Commission (the “SEC”) on June 12, 2017.

Follow Kiora Pharmaceuticals Inc (NASDAQ:KPRX)














Page 2 of 11